MedPacto wins Australian ethics approval for MP2021 Phase 1 trial

• MedPacto received HREC clearance in Australia for a Phase 1 trial of MP2021 in healthy adult volunteers.
• Trial targets up to 32 participants in a single-ascending-dose, placebo-controlled study of safety, tolerability, PK, PD.
• Study timeline set for Q4 2026 to Q4 2027, with completion targeted for Dec. 31, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedPacto Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261002901097), on October 02, 2026, and is solely responsible for the information contained therein.